Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Liabilities: 2017-2024

Historic Other Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $8.7 million.

  • Aclaris Therapeutics' Other Non-Current Liabilities rose 6.00% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 6.00%. This contributed to the annual value of $8.7 million for FY2024, which is 40.32% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Other Non-Current Liabilities stood at $8.7 million for FY2024, which was up 40.32% from $6.2 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Other Non-Current Liabilities registered a high of $33.1 million during FY2022, and its lowest value of $4.1 million during FY2020.
  • Its 3-year average for Other Non-Current Liabilities is $16.0 million, with a median of $8.7 million in 2024.
  • As far as peak fluctuations go, Aclaris Therapeutics' Other Non-Current Liabilities skyrocketed by 599.34% in 2021, and later slumped by 81.27% in 2023.
  • Aclaris Therapeutics' Other Non-Current Liabilities (Yearly) stood at $4.1 million in 2020, then spiked by 599.34% to $28.4 million in 2021, then increased by 16.55% to $33.1 million in 2022, then crashed by 81.27% to $6.2 million in 2023, then skyrocketed by 40.32% to $8.7 million in 2024.